Chronic HBV: Use of antiviral prophylaxis with biologics ‘low’
Adherence to guidelines is poor, gastroenterologists find in meta-analysis
Patients with chronic hepatitis B are missing out on antiviral prophylaxis prior to initiation of biologic agents, putting them at risk of viral reactivation, Australian doctors warn.
Results from their meta-analysis show the prevalence of reactivation after starting biologic therapy is up to nine times higher in chronic carriers of hepatitis B virus (HBV) compared to occult carriers.
